Emerging Treatment Modalities in Metastatic Breast Cancer: Highlights from SABCS 2022 and Beyond - Episode 3
Use of Second-Generation Oral SERDs in ER+/HER2- mBC
Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.
Related Content:
